The Food and Drug Administration this week released guidance for institutional review boards seeking clarity regarding the key factors and procedures they should consider when reviewing requests by physicians and others for individual patient access to investigational drugs.

A request for emergency individual patient access to an investigational drug does not require prior IRB review, but the board must be notified within five working days once treatment begins and any subsequent use of the drug is subject to IRB review, the guidance notes.

Related News Articles

Headline
The Department of Veterans Affairs July 8 will host a webinar featuring clinicians who will present a case-based educational session on performing cognitive…
Headline
The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2. The test…
Headline
The Environmental Protection Agency yesterday approved two Lysol products following testing indicating that both safely and effectively kill the virus that…
Headline
The AHA, Association of American Medical Colleges and Catholic Health Association of the United States today requested the Department of Treasury and the…
Headline
The AHA is hosting calls for all hospital and health system leaders to provide the latest information on and answer questions about the COVID-19 pandemic. The…
Blog
A recent article in the Wall Street Journal about coronavirus infections in hospitals speaks to the spread of this disease and the importance of taking…